What is Vertex Pharmaceuticals known for?
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases.
Is Vertex Pharmaceuticals a buy 2021?
Good Rank and Rising Estimates: Vertex has a Zacks Rank #1 (Strong Buy). Earnings estimates for Vertex’s earnings have risen by 10.2% for 2021 and 7.1% for 2021 over the past 60 days. Strong CF Portfolio: Vertex’s main area of focus is cystic fibrosis (CF). The CF market represents huge commercial potential.
Who founded vertex?
Joshua Boger
Vertex Pharmaceuticals/Founders
Joshua Boger is the founder of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). He retired as Vertex’s Chief Executive Officer in May 2009, after over 20-years with the company.
What is the plural of vertex?
noun. ver·tex | \ ˈvər-ˌteks \ plural vertices\ ˈvər-tə-ˌsēz \ also vertexes.
Who is the CEO of vertex Pharmaceuticals?
Reshma Kewalramani (Apr 1, 2020–)
Vertex Pharmaceuticals/CEO
When did Reshma Kewalramani become CEO?
April 1, 2020
She then entered the biopharma sector, working for Amgen for over 12 years, where she held leadership positions in research and development. In 2017 she joined Vertex Pharmaceuticals. She assumed the role of president and CEO on April 1, 2020 and is a member of the Vertex Board of Directors.
What does Vertex Pharmaceuticals do for a living?
The Science of Possibility. Vertex creates new possibilities in medicine to cure diseases and improve people’s lives. We work with leading researchers, doctors, public health experts and other collaborators who share our vision for transforming the lives of people with serious diseases, their families and society.
When did Vertex Pharmaceuticals move to Boston Massachusetts?
Since late 2011, Vertex has ranked among the top 15 best-performing companies on the Standard & Poor’s 500. Vertex shares increased 250 percent in the same period. In January 2014, Vertex completed its move from Cambridge, Massachusetts, to Boston, Massachusetts, and took residence in a new, $800 million complex.
When did Vertex Pharmaceuticals acquire Exonics Therapeutics?
In June of the same year, Vertex announced it would acquire Exonics Therapeutics for up to $1 billion and collaborate with CRISPR Therapeutics, boosting its development of treatments for Duchenne muscular dystrophy and Myotonic Dystrophy Type 1. In September 2019 the company announced it would acquire Semma Therapeutics for $950 million in cash.
What’s the name of the vertex drug for cystic fibrosis?
The combination drug is marketed under the tradename Orkambi. On 28 March 2017, Vertex announced Phase 3 data from a dual combination treatment, tezacaftor plus ivacaftor, in patients with cystic fibrosis. On 12 February 2018, the FDA approved the combination, marketed as Symdeko.